ArticleNature communications2025
Evolution of linear triterpenoid biosynthesis within the Euphorbia genus.
Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- A Bioactive Fraction of Euphorbia antiquorum Stem Powder Ameliorates High-Fat High-Fructose Diet/Streptozotocin-Induced Diabetes via GLUT-4 Modulation.Chemistry & biodiversity · 2026Article
- Advances in biotechnological methods for genetic and metabolic engineering in Methylomonas sp. DH-1.Journal of biological engineering · 2026Review
- Metabolic Engineering of Terpenoid Biosynthesis in Medicinal Plants: From Genomic Insights to Biotechnological Applications.Current issues in molecular biology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Terpenoids are among the largest classes of plant natural products. Squalene, a high value commodity in the cosmetic, food and pharmaceutical industries, is a common linear precursor for the biosynthesis of C30 triterpenes and sterols across plant, animal and fungal kingdoms. The anti-fungal compound peplusol is another linear C30 triterpene, but has only been reported in the genus Euphorbia. Here, we show that peplusol production has evolved due to duplication of a sterol synthase gene with one copy acquiring peplusol synthase activity and the original gene retaining the ancestral function. We identify a number of key amino acid residues that can convert the squalene synthase enzyme into peplusol synthase and vice versa. The PEPLUSOL SYNTHASE gene from E. peplus is able to drive significant levels of peplusol production in alternate host production platforms including Nicotiana benthamiana (over 2.5% leaf dry weight) and Saccharomyces cerevisiae (30 mg/L culture).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.